Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Coloplast on the acquisition of Atos Medical
Mandate

Vinge advises Coloplast on the acquisition of Atos Medical

November 11, 2021 Employment and Benefits Real Estate and Construction Banking and Finance Corporate Crime & Compliance IT, Telecommunications and Outsourcing Intellectual Property M&A

Vinge advises Danish healthcare company Coloplast on its acquisition of Atos Medical, the global market leader in laryngectomy for EUR 2.155 billion (around DKK 16 billion) from PAI Partners, a global private equity firm headquartered in Paris. Closing of the transaction is subject to customary regulatory approvals and anticipated to occur in Q2 2021/22.

Vinge’s team primarily consisted of Matthias Pannier, Ulrich Ziche, Vilhelm Rondahl, Clara Sohlberg and Julia Hagelberg (M&A), Klara Secher and Axel Lennartsson (IP), Lisa Hörnqvist and Mario Saad (Agreements and IT), Karl-Hugo Engdahl and Karolina Fuhrman (GDPR), Tove Lövgren Frisk (Compliance), Jolinn Uhlin and Michaela Ådén (Banking & Financing), Elin Broman (Employment) and Lina Österberg and Ulf Pyk (Real Estate). Kromann Reumert acted as lead counsel for Coloplast.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025